Press "esc" to clear
Go to Advanced Search

Showing results

110 of 2347
181022_Fanelli_postdocprize_sm1.jpg

Article ID: 702596

Physicist Takes Cues from Artificial Intelligence

Thomas Jefferson National Accelerator Facility

In the world of computing, there’s a groundswell of excitement for what is perceived as the impending revolution in artificial intelligence. Like the industrial revolution in the 19th century and the digital revolution in the 20th, the AI revolution is expected to change the way we live and work. Now, Cristiano Fanelli aims to bring the AI revolution to nuclear physics.

Released:
22-Oct-2018 3:45 PM EDT
  • Embargo expired:
    22-Oct-2018 3:15 PM EDT

Article ID: 702538

Radiation/cisplatin combination established as standard of care for HPV-related head and neck cancer

American Society for Radiation Oncology (ASTRO)

Combinations of radiation and chemotherapy drugs have been shown to cure HPV-related head and neck cancer with a high success rate. A new phase III trial has now determined that cisplatin chemotherapy, combined with radiation therapy, produces the best results and should be considered the standard of care. Findings will be presented in a news briefing Tuesday at 3pm ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
22-Oct-2018 12:05 AM EDT
Embargo will expire:
26-Oct-2018 8:00 AM EDT
Released to reporters:
22-Oct-2018 2:30 PM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 26-Oct-2018 8:00 AM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702534

Combined therapy including pelvic lymph node radiation provides significant benefit for prostate cancer patients

American Society for Radiation Oncology (ASTRO)

The first report of a large international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term hormone therapy to standard treatment can extend the amount of time before their cancer spreads. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
22-Oct-2018 12:00 AM EDT
  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702535

Radiation Therapy Outcomes Better for African-American Prostate Cancer Patients Than Caucasian Patients

American Society for Radiation Oncology (ASTRO)

While popular beliefs and population data suggest that African-American men are at higher risk of dying from prostate cancer than Caucasian men, a new analysis of genetic data from a large prospective registry and clinical data from several randomized trials indicates that African-American patients may have comparatively higher cure rates when treated with radiation therapy. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
21-Oct-2018 11:05 PM EDT
  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702536

Men with low- and intermediate-risk prostate cancer can safely benefit from fewer, higher-dose radiation treatments

American Society for Radiation Oncology (ASTRO)

Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study clears the way for patients who may wish to shorten their course of treatment without fear of increasing their risk for severe, adverse side effects. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
21-Oct-2018 11:05 PM EDT
  • Embargo expired:
    22-Oct-2018 12:00 PM EDT

Article ID: 702537

High-dose, high-precision radiation therapy safe and effective for kidney cancer patients with only one kidney

American Society for Radiation Oncology (ASTRO)

Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. Findings will be presented in a news briefing today at noon ET from the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Released:
21-Oct-2018 11:05 PM EDT
20181012_Wicks_MoviePass_1260x649-980x505.jpg

Article ID: 702563

Darden Professor Doesn’t See Bright Future for MoviePass

University of Virginia Darden School of Business

After several changes to its business model related to its service and fees (some more transparent than others), and a recent decision to automatically restore the subscriptions of customers who had previously opted out of the service, MoviePass has been under fire.

Released:
22-Oct-2018 11:05 AM EDT

Education

181018_fibers.jpg

Article ID: 702481

Award-Winning Nuclear Physics Technology Monitors Cancer Treatments

Thomas Jefferson National Accelerator Facility

Nearly a half-million cancer patients are treated with radiation therapy every year in the United States. Now, technologies developed in partnership with the Department of Energy's Thomas Jefferson National Accelerator Facility (Jefferson Lab) are helping to ensure that patients are receiving just what the doctor ordered. The technologies are featured in RadiaDyne’s OARtrac® system, which was cited as a Medical Device Engineering Breakthrough Award and as a 2018 R&D 100 award finalist by R&D Magazine.

Released:
19-Oct-2018 10:30 AM EDT
10162018_Davidson_MeToo_1260x649-980x505.jpg

Article ID: 702449

Sponsoring Women in the #Metoo Era

University of Virginia Darden School of Business

Women and men don’t differ in intelligence or business acumen, yet women continue to fly under the radar when it comes to advancement into executive positions. Christina R.’s story provides insight into why: Sometimes it’s not just what you know or who you know, but who knows you.

Released:
18-Oct-2018 4:10 PM EDT

Showing results

110 of 2347

Chat now!